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Abstract: Antibodies play a central role in prophylaxis
against many infectious agents. While neutralization is a
primary function of antibodies, the Fc- and complement-
dependent activities of these multifunctional proteins
may also be critical in their ability to provide protection
against most viruses. Protection against viral pathogens in
vivo is complex, and while virus neutralization—the ability
of antibody to inactivate virus infectivity, often measured
in vitro—is important, it is often only a partial contributor
in protection. The rapid fluorescent focus inhibition test
(RFFIT) remains the ‘‘gold standard’’ assay to measure
rabies virus–neutralizing antibodies. In addition to neu-
tralization, the rabies-specific antigen-binding activity of
antibodies may be measured through enzyme-linked
immunosorbent assays (ELISAs), as well as other available
methods. For any disease, in selecting the appropriate
assay(s) to use to assess antibody titers, assay validation
and how they are interpreted are important consider-
ations—but for a fatal disease like rabies, they are of
paramount importance. The innate limitations of a one-
dimensional laboratory test for rabies antibody measure-
ment, as well as the validation of the method of choice,
must be carefully considered in the selection of an assay
method and for the interpretation of results that might be
construed as a surrogate of protection.
Introduction
Whether an animal control worker wants to determine if a
rabies vaccine booster is necessary to establish an acceptable pre-
exposure status, or a physician is considering the causes of
encephalitis in a child, or the owner of an immunologically
compromised dog is worried that the dog’s response to rabies
vaccination will not be sufficient to pass a serological test allowing
them to travel to a rabies-free area, or a researcher is trying to
determine if the rabies vaccine-bait response is adequate in a
raccoon population, or one needs to assign a potency value to a
rabies immune globulin product, all demand an accurate
assessment based on the measurement of circulating antibodies.
In each of these situations the measurement or simply the
detection of rabies-specific virus-neutralizing or other antibodies
will help resolve the question. However, just as the circumstances
in each of these scenarios are different, the specifics of the method
chosen to measure antibodies, the regulatory requirements of the
testing, and the purpose of testing in each of these situations are
different. Antibodies arise from the humoral immune response to
rabies antigens, the process of which is controlled by many factors,
including the amount of antigen, route of delivery, the expression
and involvement of major histocompatibility complex (MHC)
genes, and the health status of the individual, among others. An
understanding of the host immune response, including the
immunoglobulin (Ig) subclass (type) and the kinetics and longevity
of the response, is necessary to obtain the measure or degree of
rabies immunity.
Initially, measurement of rabies virus neutralizing antibodies
(RVNA) was performed in vivo using the mouse neutralization test
(MNT). Subsequently, the rapid fluorescent focus inhibition test
(RFFIT) was established as the ‘‘gold standard’’ in vitro test [1].
Methods for measuring rabies immunity vary with regard to the
humoral component measured (i.e., the Ig subclass or functional
activity) and performance characteristics (i.e., specificity or
sensitivity), as well as the cost and complexity of the method.
Understanding each of these unique factors is essential in the
selection and proper use of the method and is equally critical in the
interpretation of the results derived from the methods. Moreover,
regulations (e.g., from the United States Food and Drug
Administration (USFDA), European Union, World Organization
for Animal Health) that require validated and approved test
methods for measuring the generation of rabies virus antibodies
are relevant in pet transport and in rabies biologics production and
evaluation, for use in both humans and animals. In this review, we
discuss the following (1) the role of rabies-specific antibodies in
disease prevention, (2) the methods that can be used for detection
and measurement, and (3) the considerations and current
requirements for method standardization and validation.
Methods
A review of the literature was conducted using the online
database PubMed from 1975 to 2008 with US National Library of
Medicine medical subject headings (MeSH). Reference lists of
selected articles and reviews were also individually researched. In
addition, unpublished rabies serology data from the Kansas State
University Rabies Laboratory were reviewed.
The Role of Rabies-Specific Antibodies in Disease
Prevention
Animal models of protection against rabies have demonstrated
the essential role of RVNA [2,3]. Indeed, RVNA alone can result
in viral clearance from the central nervous system (CNS) of
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www.plosntds.org 1 March 2010 | Volume 4 | Issue 3 | e595experimentally infected mice [4]. Most rabies-specific antibodies
are directed to epitopes on the rabies virus glycoprotein, although
some may specifically recognize the nucleoprotein [5,6]. How
rabies-specific antibodies neutralize the virus is not entirely
understood in terms of what specific epitopes or Ig subclasses
are involved [7,8]. A single rabies virion can bind up to 1,000
molecules of some antiglycoprotein monoclonal antibodies without
being neutralized, suggesting that virus neutralization probably
involves more than simply antibody binding to virion epitopes
[7,8]. It can be assumed that antibodies that neutralize virus in
vitro are more efficient in the process that leads to protection
against virus infection in vivo than antibodies that do not
neutralize virus in vitro. The Fc portion of antibodies alone has
specific biological functions, including activation of antigen-
presenting cells and the complement cascade. As such, whole
IgG is expected to be more potent than the epitope-specific F(ab)
2
portions of neutralizing antibodies [9]. With the development of
molecular techniques for engineering the specificity of antibody
Fab fragments and intact monoclonal antibodies for diagnostic
and therapeutic purposes, the importance of understanding how
antibodies neutralize rabies virus mechanistically becomes all the
more important. Because it is difficult in practical terms to predict
the ability of a polyclonal or monoclonal antibody preparation to
neutralize virus by measurements of antibody avidity or affinity
alone, neutralization activity must be determined first by some
means in vitro even if only to provide an estimate of in vivo
activity. That said, a preparation of rabies-specific antibodies that
demonstrates potent neutralization in vitro may still not protect in
vivo [10].
The rabies virus is highly neurotropic. Within the CNS, rabies
virus infectiondevelopsforthe mostpart undetectedbythe adaptive
immune responses of the host until the infection is in its final stages.
In addition to an infection that develops within this immune-
privileged site, the rabies virus is able to subvert any host immune
response thatismounted and thustheoutcomeofinfectionisfatalin
nearly 100% of cases. In contrast, a rabies vaccine is able to
stimulate high levels of circulating RVNA. This is why immunity
following exposure to rabies virus in an unvaccinated individual,
initiated with prompt wound cleansing to reduce viral load at the
site of exposure and administration of rabies-specific Ig followed by
a series of rabies vaccinations, is virtually 100% effective in
preventing infection. Passive protection with rabies Ig (RIG) is
critical to immediately neutralize a majority of infectious virions,
keeping the virus from spreading while waiting for induction of the
host’s adaptive immune response. In general, rabies vaccines
historically are killed whole-virus vaccines, which are expected to
promote the development of anti-rabies virus-specific antibodies
along with a CD4
+ T lymphocyte response, which includes cytokine
production. Each individual’s polyclonal antibody response to
rabies vaccination is a unique mix of specificities to rabies virus
antigens. Although the majority of individuals develop a variety of
measurable antibodies in response to pre- or postexposure
vaccination, there may be substantial variation in the neutralizing
activity and quantity of RVNA produced.
Antibodies develop out of intrinsic host responses and in
response to extrinsic factors such as the amount of antigen given,
type of antigen, and route of exposure or vaccination. For
example, it has been demonstrated that the more potent the
vaccine the higher the levels of RVNA that are induced in human
subjects [11]. Other studies have demonstrated that the type of
vaccine and route of vaccination affect the level of antibodies at
both 14 days and one year after vaccination [12]. Also, a T helper
type 2 (Th2) immune response to killed vaccine is inherently
different from activation of a T helper type 1 (Th1) immunity by a
live virus vaccine. In addition to host factors such as age and
general health status, an individual’s adaptive immune response
requires the binding of foreign peptides to the MHC molecule on
antigen-presenting cells and stimulation of a corresponding T cell
clone by that particular MHC–peptide combination. The diversity
of the genes in the MHC complex, consisting of hundreds of
alleles, influences the variation in the immune response to
vaccination [13]. Humoral (Th2) and cellular (Th1) type immune
responses are largely directed by the production of cytokines,
including maturation of the antibody response and generation of
Ig subclass. A dichotomy of responses in rabies vaccination among
humans to high or good responders and poor or low responders
has also been observed [14]. Predictions regarding the longevity of
the RVNA response can be made on the basis of the level and
timing of the peak response to vaccination [12,14].
Methods for the Detection and Measurement of Rabies
Virus Antibodies
Methods available for the detection and measurement of rabies
virus–specific antibodies are either antigen-binding assays or virus-
neutralization assays. In antigen-binding assays, antibodies in
serum or cerebrospinal fluid (CSF) are detected, quantified, and
characterized by their ability to bind to various rabies virus
antigens, from whole virus, purified subunits, or specific peptides
that mimic epitopes. Such assays determine the affinity, avidity,
and specificity of binding antibodies. Commonly, these methods
involve fixing the antigen to a solid surface, i.e., tube, plate, or
bead. The interaction between the antibody and the antigen is
then visualized and quantitated by various detection systems that
involve color development through an enzyme–substrate reaction
or binding of a secondary antibody, conjugated to a fluorescent
marker or staphylococcal protein A/G, to the primary antibody
bound to the antigen. These assays can be used to measure
antibodies that react to internal viral proteins, either structural or
enzymatic, as well as to estimate levels of antibodies that bind to
the external proteins against which neutralizing antibodies are
directed. In contrast, modern virus neutralization assays are cell-
based assays that detect the functional activity of antibodies in the
serum or CSF against live virus. The mechanism of virus
neutralization in cell culture (an in vitro assay) depends upon the
interaction between the virion epitope and the paratope (the
specific counteracting site) of the antibody, and may also be
influenced by receptor characteristics of the cells upon which an
assay is performed [15]. Evidence indicates that the virus infects
cells of neuronal origin using the receptors nicotinic acetylcholine
receptor, the low-affinity nerve growth factor receptor, or the
neural cell adhesion molecule, while infecting non-CNS cells by
use of other unidentified receptors [16,17]. The outcome of a
virus-neutralization assay is based on a measurement of virus
growth in cell culture, i.e., defining whether virus escapes
neutralization or not. Binding assays, on the other hand, measure
a different set of characteristics of the rabies-specific Ig response
compared with neutralization assays. Hence, the results from
binding assays are not, a priori, directly comparable to
neutralization results [7]. With appropriate validation and
suitability for the intended purpose, binding assays can be used
to determine the presence or absence of antigen-specific
antibodies, and in some cases Ig subclasses, that could be used
as an approximation or confirmation of the neutralizing antibody
response. The purpose of testing will determine which methods are
most appropriate. For example, detection of specific rabies virus
antibodies in the CSF is diagnostic of rabies infection, whether the
test performed is one of the binding assays (such as to fixed whole
virus on a slide that is detected with anti-species IgG or IgM) or a
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detected in sera may be an indication of prior vaccination or, if
present with clinical signs of rabies, of active infection or even, in
very rare cases, prior exposure to rabies virus that resulted in no
clinical infection [18] or in survival of the infection by the
individual [19]. To fully define immunity to rabies requires a
highly specific assay and the ability to detect extremely low levels
of antibodies, and often of specific subclasses such as IgM and IgG.
Binding assays can more easily be devised to achieve these
requirements through use of specific, pure antigen and robust
detection (readout) systems. Nonetheless, a measure of protection
against rabies infection is best approximated by a virus
neutralization test. Since experimental virus challenge methods
will never be performed in humans, surrogate experimental animal
models of protection based on field observations and the amount
and duration of serum neutralizing antibodies measured by in
vitro methods are used.
By changing various components, such as virus strain, detection
system, etc., of the assay, it is possible to custom design a ‘‘fit-for-
purpose’’ assay. For example, detection of RVNA in a particular
colony of bat species associated with a rabies virus variant may be
‘‘specifically’’ measured using, in the in vitro assay, the suspected
rabies virus variant in circulation among the bats as the challenge
virus. The sensitivity of a test method may be adjusted by varying
the amount of antigen or challenge virus dose to more precisely
define and determine low levels of antibodies or the presence of
nonspecific or cross-reacting antibodies or substances. For binding
assays, such as an enzyme-linked immunosorbent assay (ELISA), a
labeled anti-IgM as the secondary antibody detects only IgM
rabies virus antibodies as the primary antibody. The anti-IgM
level can be compared to the anti-IgG level in the same sample by
performing the same assay, but using a labeled anti-IgG as the
secondary antibody. The competitive ELISA method utilizes a
competing monoclonal antibody to a rabies protein epitope and
measures the ability of antibodies in the test sample (of serum or
CSF) to out-compete the monoclonal antibody for attachment to
that particular epitope [20]. This makes the assay very specific for
measuring antibodies that bind to a specific epitope on a given
rabies protein [21]. In addition, variation can be introduced to
assay methods to make them easier to perform and easier to
standardize for use in very diverse environments and laboratories.
For example, molecular techniques involving pseudotyped viruses
as vectors, such as the lentiviral vector system, to express the rabies
glycoprotein have several advantages. They provide the ability to
(a) standardize the target epitope; (b) test for neutralization against
multiple strains or genotypes of viruses; (c) use a lower level of
biohazard practices (i.e., making them potentially safer than using
live rabies virus), and (d) improve the economy of the test methods
[22]. These are some of the factors to consider when choosing the
method that is ‘‘fit-for-purpose.’’
Determination of the cut-off value (i.e., the point that indicates
seroconversion or determination of adequate vaccination) is
specific for each test method and is critical to how results are
interpreted. In general, a serum neutralization titer of 1:100 (90%
endpoint titer) is acceptable as effective, even though antibody
levels in tissue might actually be lower [23]. The antibody titer
(level) of 0.5 IU (international units)/mL, which is recognized
globally, was first mentioned in the Eighth Report of the World
Health Organization (WHO) Expert Committee on Rabies, 1992.
With regard to pre-exposure vaccination, the report states: ‘‘All
persons who work with live rabies virus in a diagnostic, research or
vaccine production laboratory should have a serum sample tested
for rabies virus-neutralizing antibodies and a booster administered
when the titre falls below 0.5 IU/mL.’’ The report also
recommends that the level of RVNA be determined by the
MNT or the RFFIT, using a common challenge virus strain [24].
It is clear that the level of 0.5 IU/mL was established as an
indication of adequate vaccination (not protection!) in humans at
risk of rabies exposure, and that it refers to using a serum
neutralization test with a standard challenge virus strain. In the
US, the recommendations of the Advisory Committee on
Immunization Practices (ACIP) state ‘‘If the titer falls below the
minimum acceptable antibody level of complete neutralization at a
serum dilution of 1:5, a single pre-exposure booster dose of vaccine
is recommended for persons at continuous or frequent risk for
exposure to rabies’’ (the minimum acceptable antibody level is not
defined in IU/mL) and recommend the RFFIT method for testing
[25]. Therefore, when other methods are employed to measure
rabies-specific antibodies in humans or when the RFFIT is
employed for other species (not humans), the accepted level of
0.5 IU/mL may not apply. In a review of rabies challenge studies,
valid cut-off values for RFFIT results in cats and dogs of 0.1 and
0.2 IU/mL, respectively, were suggested [2]. The level of 0.5 IU/
mL by RFFIT or FAVN methods is recognized by regulatory
authorities from most rabies-free areas as proof of adequate
response to vaccination for importation of cats and dogs [26].
When results of testing raccoon sera by both RFFIT and a
commercial veterinary ELISA kit are compared, similar measures
of sensitivity and specificity are obtained only when using different
cut-off values (see Table 1). For raccoon sera tested by RFFIT,
setting the cut-off level at 0.5 IU/mL allows for the possibility of
nonspecific inhibitors to be present in the sera of wildlife, which
may give false-positive results if the cut-off level is set too low.
Often the ELISA method is less susceptible to interfering
substances because the serum dilution used in the assay is
generally higher. Measurements above 0.1 EU (equivalent
units)/mL appear to be specific for this set of samples, using this
particular test kit. When monitoring bait uptake in raccoons in
oral baiting programs, it is more important to use a method that
estimates levels of potential immunity of a population than to
determine the degree of protection in an individual raccoon.
Employing different cut-off values in studies when comparing
results produced with the same method can result in misleading
conclusions. Therefore, the assay and cut-off value that can
distinguish vaccinated from unvaccinated raccoons becomes the
best ‘‘fit-for-purpose’’ method. Similarly, the cut-off level is
significant in a study of the human response to a rabies vaccine
that compares three ELISA methods against the RFFIT method
utilizing the seroconversion cut-off value of 0.5 IU/mL [27].
Calculations and hence conclusions derived from the seroconver-
sion RFFIT results will vary depending on the cut-off level used,
either 0.5 IU/mL or the ACIP-accepted level of complete
neutralization at a 1:5 dilution. For example, determination of
sensitivity and specificity measures of the ELISA methods in
comparison with RFFIT results, interpreted as negative or positive
for seroconversion by the ACIP level, rather than the 0.5 IU/ml
level used in the paper, will give different values [27]. In these two
examples, the appropriate cut-off value should be determined by
and specific to each method, and in relation to the purpose of
testing and regulatory requirements. In addition to setting
appropriate cut-off levels for particular methods, regulatory
agencies, such as the European Pharmacopoeia, the USFDA, or
national import authorities in rabies-free areas, may also require
laboratory validation and approval or certification.
Method Standardization and Validation
Standardization of rabies serologic test methods is essential to
provide a meaningful comparison of antibody characteristics and
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especially relevant when rabies serology results are compared
between different laboratories and different studies over time. The
fluorescent antibody virus neutralization (FAVN) test was
developed in part to address standardization of the various
modifications of the RFFIT in use [28]. Variables in the test,
which include the challenge virus, antibodies, target cells, and cut-
off values, must be standardized for the test results to be
comparable. For example, with whole rabies virus versus rabies
virus glycoprotein as the antigen in an indirect ELISA test, where
all the other variables are standardized, results would not be
expected to be comparable. In most test samples, the majority of
the rabies virus antibodies being analyzed will be directed against
the glycoprotein, but antibodies to nucleoprotein and phospho-
protein antigens of the virus are not uncommon and will be
detected in an indirect ELISA based on the whole virus [29]. In
the measurement of potency of monoclonal antibodies, it is
important to consider that the specificity of an antibody for a
single epitope may not be sufficient to neutralize all epitope
(antigenic) variations of a challenge virus strain or even a number
of quasispecies within a single virus stock [30,31]. Similarly,
different challenge virus strains can influence the results obtained
in serum neutralization testing. In a study of human subjects that
compared serum titers measured in vitro against challenge virus
strains that were either homologous or heterologous to the vaccine
strain revealed that, in the majority of subjects, higher titers were
detected against the homologous strain [32]. Also, both high and
low challenge virus doses can affect the determination of rabies Ig
potency [33]. The use of a recognized standard anti-rabies serum
control as a reference will standardize the results of a method and
allow for conversion of the measurements (e.g., titers, optical
density readings, etc.) into recognized units such as IU/mL or
EU/mL.
The international reference standards for RIG products in use
today include of the WHO first International Standard for Rabies
Immunoglobulin, the WHO second International Standard for
Rabies Immunoglobulin, and the Office International des E ´pizooties
(OIE) canine RIG reference serum. The potency of each of these
products has been assigned a value by serum neutralization methods
[34–36]. The original international standard RIG reference serum,
which was of equine origin, was established in 1955. Based on the
lyophilized product weight of 86.6 mg per ampoule, a potency value
of 86.6 IU was assigned. The WHO first RIG reference serum of
human origin was prepared from pooled sera from vaccinated
humans. The human RIG potency was established by interlabora-
tory testing against the standard equine RIG in a RFFIT performed
in six laboratories. The test involved two dilutions (low and high) of
the product in four replicate assays. After statistical analysis, a
potency of 59 IU was assigned in 1984 to the WHO first
International Standard for RIG. In a similar manner, a second
pool of sera from vaccinated humans was tested in 1993, assigned a
potency of 30 IU, and established as the WHO second International
Standard for RIG reference serum. The RIG reference serum used
inthe US, Lot R-3, is a portion of the lot that became the WHO first
International Standard for RIG reference serum. The OIE canine
RIG reference serum has a potency of 6.7 IU, and batches of this
product are calibrated against the WHO second International
Standard for RIG reference serum. The relative potencies of these
two WHO human RIG reference sera were compared by the
USFDA in 1997 and again by Kansas State University Rabies
Laboratory in 2006. This comparison showed a decrease in the
relative potency of WHO first International Standard in relation to
thepotencyofWHOsecondInternationalStandardof2.5%in1997
and 14% in 2006. These differences are not considered statistically
significant, but they illustrate the effect of using different reference
standards when comparing rabies serology results and the
importance of quality control monitoring and standards.
The use of potency values for RIG that are assigned by serum
neutralization methods as opposed to those assigned by binding
assays is inappropriate and problematic. Figure 1 illustrates the
discrepancies that can occur when various RIG reference sera of
the same potency determined by serum neutralization are used to
calculate potency values obtained by an ELISA method. When the
WHO first and second RIG reference sera are diluted to 2.0 IU/
mL to give similar potency values by RFFIT, the ELISA results
are discrepant. Thus, if the WHO first RIG is used as the
reference control for the standard curve in an ELISA assay, lower
results will be obtained than if the WHO second RIG is used.
‘‘Method-of-result’’ calculation is an additional factor to consider
in the standardization of an assay. For example, the use of either
50% or 100% endpoint titers, both of which can be calculated for
serum neutralization assays, will yield different titer values. For any
comparison of results, it is essential to know, and should always be
stated, what calculation was used to generate titer values.
Table 1. Summary of rabies serology results of 100 raccoon subjects (50 vaccinated/50 unvaccinated) comparing RFFIT and ELISA
methods.
Cut-off level Vaccination Status Specificity Sensitivity
Yes No
0.1 IU/mL or EU/mL ELISA Result # above cut-off 35 0 1.00 0.77
# below cut-off 15 50
RFFIT Result # above cut-off 42 10 0.83 0.86
# below cut-off 8 40
0.5 IU/mL or EU/mL ELISA Result # above cut-off 24 0 1.00 0.66
# below cut-off 26 50
RFFIT Result # above cut-off 32 1 0.98 0.74
# below cut-off 18 49
Two cut-off values for seroconversion (0.1 IU/mL and 0.5 IU/mL were used for determination of specificity and sensitivity in relation to vaccination status. Raccoons
were wild-caught. Vaccinated raccoons were orally vaccinated with V-RG. Blood samples were drawn at various time-points after vaccination and tested by RFFIT and
ELISA (Bio-Rad Platelia Rabies Kit II).
doi:10.1371/journal.pntd.0000595.t001
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It is important that characteristics and variability associated
with different assay methods that define antibody titers continue to
be defined as we advance our understanding of immunity and
disease prevention. The measurement of rabies specific antibodies
in vitro is essential and should be the first step taken to establish
whether rabies immunity following vaccination is successful. Even
so, in vitro measurements may never completely correlate with
what may be regarded as protective in vivo. Even use of ‘‘gold
standard’’ measurements of rabies virus neutralizing activity in
vitro provides only an estimate of protection. Despite the long
history of using virus neutralization tests, there are still no
internationally recognized standard protocols for measuring
rabies-specific antibodies, for specifically defining RIG potency
for human rabies biologics formulation, or for assessing oral rabies
vaccine uptake in wildlife. Method standardization requires the
careful examination and evaluation of laboratory test perfor-
mance, which may include audits of laboratory operations, the
publication and sharing of standard operating procedures, and
inter- and intralaboratory evaluation of proficiency in performing
tests. Proficiency testing, training, and certification, as well as
Figure 1. International standard RIG reference sera. WHO first SRIG and WHO second SRIG were diluted to 2.0 IU/mL according to the potency
as labeled. The SRIG preparations were evaluated in three independent test batches by both RFFIT and ELISA (Bio-Rad Platelia Rabies Kit II) methods.
The IU/mL value was calculated against the WHO first SRIG and the EU/mL was calculated against the kit standard. Displayed are the average IU/mL or
EU/mL values with one standard deviation.
doi:10.1371/journal.pntd.0000595.g001
Box 1. Learning Points
1. RVNA have been demonstrated to be critical for
protection against rabies. Even so, in vitro measurements
are only a partial determination of the degree of
protection provided in vivo. Not all methods that measure
rabies-specific antibodies will determine the neutralizing
function of the antibodies.
2. In the selection of the most appropriate assay for rabies
antibody detection, consideration of the purpose and use
of the results is as important as the established
performance characteristic of the assay.
3. Standardization of assays includes both assay compo-
nents and test conditions. Alterations will cause variation
in results; therefore use of a particular assay (e.g., ELISA or
serum neutralization) does not guarantee comparable
results if the assays have not been standardized.
4. Because rabies is a fatal disease for which development
of a sufficient RVNA response is paramount for protection,
assay specificity, sensitivity, and accuracy must be verified
for meaningful clinical decisions to be made based on the
results.
5. Steps toward better understanding and use of rabies
serology assays will include collaboration of national
laboratories, regulatory agencies, as well as commercial
and research laboratories. Greater cooperation and stan-
dardization of rabies serology assays will lead to increased
understanding of the relationship between in vitro
measurement and in vivo protection.
Box 2. Key References in the Field
1. Smith JS, Yager PA, Baer GM (1973) A rapid reproducible
test for determining rabies neutralizing antibody. Bull
World Health Organ 48: 535–541.
2. Cliquet F, Aubert M, Sagne L (1998) Development of a
fluorescent antibody virus neutralisation test (FAVN test)
for the quantitation of rabies-neutralising antibody. J
Immunol Methods 212: 79–87.
3. Aubert MF (1992) Practical significance of rabies
antibodies in cats and dogs. Rev Sci Tech 11: 735–760.
4. Grassi M, Wandeler AI, Peterhans E (1989) Enzyme-linked
immunosorbent assay for determination of antibodies to
the envelope glycoprotein of rabies virus. J Clin Microbiol
27: 899–902.
5. Irie T, Kawai A (2002) Studies on the different conditions
for rabies virus neutralization by monoclonal antibodies
#1-46-12 and #7-1-9. J Gen Virol 83: 3045–3053.
www.plosntds.org 5 March 2010 | Volume 4 | Issue 3 | e595trends in assay performance are components of quality assurance
programs to ensure continuing adherence to acknowledged and
accepted standards. These efforts will require the collaboration of
all organizations performing tests, including national laboratories,
regulatory agencies, commercial companies, and rabies diagnostic
and research laboratories.
For a fatal disease such as rabies, where vaccination and passive
immunity (use of HRIG) are absolutely required for protection
upon exposure, verification of the accuracy and efficacy of every
assay involved in predicting the relevant in vivo protection against
the virus is vital. Moreover, there is a basic requirement to confirm
the appropriateness and applicability of any neutralization test
system or antigen binding assay used, as a predictor of in vivo
protection, with each new type of prophylactic biologic, be it a
vaccine, Ig, or monoclonal antibody formulation. In the case of
vaccines, it is imperative to understand how antibodies neutralize
viral infectivity in order to have input into the design and
presentation of immunogens of the vaccine that elicit the
specificity and isotype of antibody produced to confer the
maximum neutralizing, and ultimately, protective activity.
Supporting Information
Alternative Language Abstract S1 French translation of the
abstract by Celine Jiron Corrales.
Found at: doi:10.1371/journal.pntd.0000595.s001 (0.03 MB
DOC)
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